Zerlasiran 12 items
Trials, agents, guidance
- Agent Zerlasiran (SLN360)
- Trial ALPACAR (zerlasiran phase 2)
Studies
- ALPACAR: zerlasiran lowers time-averaged Lp(a) by more than 80 percent over 36 weeks in ASCVD (Nissen et al., JAMA 2024)
- APOLLO: single ascending doses of SLN360 (zerlasiran) lower Lp(a) by up to 98 percent (Nissen et al., JAMA 2022)
- Zerlasiran single and multiple doses in ASCVD patients: Lp(a) down 90 percent at 201 days after two doses (Nissen et al., JAMA 2024)
- Olpasiran ranks as the most effective Lp(a)-lowering therapy, network meta-analysis of 1,432 patients (Front Cardiovasc Med 2026)
- Zerlasiran cuts Lp(a) by up to 97.8% in a Japanese phase 1 trial of 18 participants (J Atheroscler Thromb 2026)
- Zerlasiran cuts Lp(a) by 80% or more at 36 weeks in phase 2, review of mechanisms and evidence (Cardiovasc Hematol Disord Drug Targets 2026)
- Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives
